Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 319

1.

The Metabolic Inhibitor CPI-613 Negates Treatment Enrichment of Ovarian Cancer Stem Cells.

Bellio C, DiGloria C, Spriggs DR, Foster R, Growdon WB, Rueda BR.

Cancers (Basel). 2019 Oct 29;11(11). pii: E1678. doi: 10.3390/cancers11111678.

2.

Case 18-2019: A 24-Year-Old Woman with a Pelvic Mass.

Spriggs DR, Melamed A, Li W, Safdar N.

N Engl J Med. 2019 Jun 13;380(24):2361-2369. doi: 10.1056/NEJMcpc1900593. No abstract available.

PMID:
31189041
3.

Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference.

Bast RC Jr, Matulonis UA, Sood AK, Ahmed AA, Amobi AE, Balkwill FR, Wielgos-Bonvallet M, Bowtell DDL, Brenton JD, Brugge JS, Coleman RL, Draetta GF, Doberstein K, Drapkin RI, Eckert MA, Edwards RP, Elias KM, Ennis D, Futreal A, Gershenson DM, Greenberg RA, Huntsman DG, Ji JXY, Kohn EC, Iavarone C, Lengyel ER, Levine DA, Lord CJ, Lu Z, Mills GB, Modugno F, Nelson BH, Odunsi K, Pilsworth JA, Rottapel RK, Powell DJ Jr, Shen L, Shih IM, Spriggs DR, Walton J, Zhang K, Zhang R, Zou L.

Cancer. 2019 Jun 15;125(12):1963-1972. doi: 10.1002/cncr.32004. Epub 2019 Mar 5.

PMID:
30835824
4.

Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma.

Zhao Y, Cao J, Melamed A, Worley M, Gockley A, Jones D, Nia HT, Zhang Y, Stylianopoulos T, Kumar AS, Mpekris F, Datta M, Sun Y, Wu L, Gao X, Yeku O, Del Carmen MG, Spriggs DR, Jain RK, Xu L.

Proc Natl Acad Sci U S A. 2019 Feb 5;116(6):2210-2219. doi: 10.1073/pnas.1818357116. Epub 2019 Jan 18.

5.

Progress in BRCA-Mutated Ovarian Cancer.

Spriggs DR, Longo DL.

N Engl J Med. 2018 Dec 27;379(26):2567-2568. doi: 10.1056/NEJMe1812644. No abstract available.

PMID:
30586521
6.

Management of feeding decisions in hospitalised adults with severe oropharyngeal dysphagia.

McHutchison L, Miles A, Spriggs D, Jayathissa S.

Australas J Ageing. 2018 Dec;37(4):E120-E126. doi: 10.1111/ajag.12562. Epub 2018 Aug 1.

PMID:
30069993
7.

Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer.

Soumerai TE, Donoghue MTA, Bandlamudi C, Srinivasan P, Chang MT, Zamarin D, Cadoo KA, Grisham RN, O'Cearbhaill RE, Tew WP, Konner JA, Hensley ML, Makker V, Sabbatini P, Spriggs DR, Troso-Sandoval TA, Charen AS, Friedman C, Gorsky M, Schweber SJ, Middha S, Murali R, Chiang S, Park KJ, Soslow RA, Ladanyi M, Li BT, Mueller J, Weigelt B, Zehir A, Berger MF, Abu-Rustum NR, Aghajanian C, DeLair DF, Solit DB, Taylor BS, Hyman DM.

Clin Cancer Res. 2018 Dec 1;24(23):5939-5947. doi: 10.1158/1078-0432.CCR-18-0412. Epub 2018 Aug 1.

PMID:
30068706
8.

Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials.

Yokota T, Bendell J, LoRusso P, Tsushima T, Desai V, Kenmotsu H, Watanabe J, Ono A, Murugesan B, Silva J, Naito T, Greenberg J, Kumar P, Wang Y, Jikoh T, Shiga R, Hyman DM, Ho AL, Spriggs DR, Schwartz GK, Gounder MM.

Br J Cancer. 2018 Jun;118(12):1571-1579. doi: 10.1038/s41416-018-0102-1. Epub 2018 May 24.

9.

A Randomized Trial of Prophylactic Extended Carboplatin Infusion to Reduce Hypersensitivity Reactions in Recurrent Ovarian Cancer.

LaVigne K, Hyman DM, Zhou QC, Iasonos A, Tew WP, Aghajanian C, Makker V, Hensley ML, Konner J, Grisham RN, Cangemi N, Soldan K, Spriggs DR, Sabbatini PJ, OʼCearbhaill RE.

Int J Gynecol Cancer. 2018 Jul;28(6):1176-1182. doi: 10.1097/IGC.0000000000001280.

10.

Ovarian Cancer Treatment - Are We Getting Warmer?

Spriggs DR, Zivanovic O.

N Engl J Med. 2018 Jan 18;378(3):293-294. doi: 10.1056/NEJMe1714556. No abstract available.

PMID:
29342385
11.

Safety and efficacy of the next generation Resolute Onyx zotarolimus-eluting stent: Primary outcome of the RESOLUTE ONYX core trial.

Price MJ, Shlofmitz RA, Spriggs DJ, Haldis TA, Myers P, Popma Almonacid A, Maehara A, Dauler M, Peng Y, Mehran R.

Catheter Cardiovasc Interv. 2018 Aug 1;92(2):253-259. doi: 10.1002/ccd.27322. Epub 2017 Sep 23.

PMID:
28940882
12.

Time to publication of oncology trials and why some trials are never published.

Chapman PB, Liu NJ, Zhou Q, Iasonos A, Hanley S, Bosl GJ, Spriggs DR.

PLoS One. 2017 Sep 21;12(9):e0184025. doi: 10.1371/journal.pone.0184025. eCollection 2017.

13.

Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment.

Yeku OO, Purdon TJ, Koneru M, Spriggs D, Brentjens RJ.

Sci Rep. 2017 Sep 5;7(1):10541. doi: 10.1038/s41598-017-10940-8.

14.

First Report of the Resolute Onyx 2.0-mm Zotarolimus-Eluting Stent for the Treatment of Coronary Lesions With Very Small Reference Vessel Diameter.

Price MJ, Saito S, Shlofmitz RA, Spriggs DJ, Attubato M, McLaurin B, Popma Almonacid A, Brar S, Liu M, Moe E, Mehran R.

JACC Cardiovasc Interv. 2017 Jul 24;10(14):1381-1388. doi: 10.1016/j.jcin.2017.05.004.

15.

Antibodies Against Specific MUC16 Glycosylation Sites Inhibit Ovarian Cancer Growth.

Rao TD, Fernández-Tejada A, Axelrod A, Rosales N, Yan X, Thapi S, Wang A, Park KJ, Nemieboka B, Xiang J, Lewis JS, Olvera N, Levine DA, Danishefsky SJ, Spriggs DR.

ACS Chem Biol. 2017 Aug 18;12(8):2085-2096. doi: 10.1021/acschembio.7b00305. Epub 2017 Jun 28.

16.

PARP Inhibitors in Ovarian Cancer Treatment.

Spriggs DR, Longo DL.

N Engl J Med. 2016 Dec 1;375(22):2197-2198. No abstract available.

PMID:
27959768
17.

Tumor Inhibition by Enzalutamide in a Xenograft Model of Ovarian Cancer.

Park BY, Grisham RN, den Hollander B, Thapi D, Berman T, de Stanchina E, Zhou Q, Iyer G, Aghajanian C, Spriggs DR.

Cancer Invest. 2016 Nov 25;34(10):517-520. Epub 2016 Nov 8.

18.

CLINICAL DECISIONS. Chemotherapy-Induced Nausea and Vomiting.

Wilbur MB, Birrer MJ, Spriggs DR.

N Engl J Med. 2016 Jul 14;375(2):177-9. doi: 10.1056/NEJMclde1607577. No abstract available.

PMID:
27410928
19.

Followership: a critical shortfall in health leadership.

Spriggs DA.

Intern Med J. 2016 May;46(5):637-8. doi: 10.1111/imj.12993. No abstract available.

PMID:
27170247
20.

A Phase I Study of Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission.

O'Cearbhaill RE, Ragupathi G, Zhu J, Wan Q, Mironov S, Yang G, Spassova MK, Iasonos A, Kravetz S, Ouerfelli O, Spriggs DR, Danishefsky SJ, Sabbatini PJ.

Cancers (Basel). 2016 Apr 22;8(4). pii: E46. doi: 10.3390/cancers8040046.

21.

Measuring Toxicity in Phase I Clinical Trials--Letter.

Hyman DM, Eaton A, Ivy SP, Spriggs DR, Iasonos A.

Clin Cancer Res. 2016 Apr 1;22(7):1828. doi: 10.1158/1078-0432.CCR-15-3043. No abstract available.

22.

Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program.

Drilon A, Eaton AA, Schindler K, Gounder MM, Spriggs DR, Harris P, Ivy SP, Iasonos A, Lacouture ME, Hyman DM.

Cancer. 2016 Apr 15;122(8):1228-37. doi: 10.1002/cncr.29918. Epub 2016 Feb 24.

23.

Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.

Dizon DS, Krilov L, Cohen E, Gangadhar T, Ganz PA, Hensing TA, Hunger S, Krishnamurthi SS, Lassman AB, Markham MJ, Mayer E, Neuss M, Pal SK, Richardson LC, Schilsky R, Schwartz GK, Spriggs DR, Villalona-Calero MA, Villani G, Masters G.

J Clin Oncol. 2016 Mar 20;34(9):987-1011. doi: 10.1200/JCO.2015.65.8427. Epub 2016 Feb 4. No abstract available.

24.

Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee.

Seymour L, Groshen S, Rosner GL, Sullivan DM, Spriggs DR, Reeves S, Gravell A, Ivy SP, Ratain MJ.

Clin Cancer Res. 2015 Nov 15;21(22):5057-63. doi: 10.1158/1078-0432.CCR-15-0035.

25.

Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated Toxicities.

Eaton A, Iasonos A, Gounder MM, Pamer EG, Drilon A, Vulih D, Smith GL, Ivy SP, Spriggs DR, Hyman DM.

Clin Cancer Res. 2016 Feb 1;22(3):553-9. doi: 10.1158/1078-0432.CCR-15-0339. Epub 2015 Aug 31.

26.

Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.

Grisham RN, Sylvester BE, Won H, McDermott G, DeLair D, Ramirez R, Yao Z, Shen R, Dao F, Bogomolniy F, Makker V, Sala E, Soumerai TE, Hyman DM, Socci ND, Viale A, Gershenson DM, Farley J, Levine DA, Rosen N, Berger MF, Spriggs DR, Aghajanian CA, Solit DB, Iyer G.

J Clin Oncol. 2015 Dec 1;33(34):4099-105. doi: 10.1200/JCO.2015.62.4726. Epub 2015 Aug 31.

27.

Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion.

Rao TD, Tian H, Ma X, Yan X, Thapi S, Schultz N, Rosales N, Monette S, Wang A, Hyman DM, Levine DA, Solit D, Spriggs DR.

PLoS One. 2015 May 12;10(5):e0126633. doi: 10.1371/journal.pone.0126633. eCollection 2015.

28.

IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo.

Koneru M, Purdon TJ, Spriggs D, Koneru S, Brentjens RJ.

Oncoimmunology. 2015 Jan 23;4(3):e994446. eCollection 2015 Mar.

29.

A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer.

Koneru M, O'Cearbhaill R, Pendharkar S, Spriggs DR, Brentjens RJ.

J Transl Med. 2015 Mar 28;13:102. doi: 10.1186/s12967-015-0460-x.

30.

Predictors of early treatment discontinuation in patients enrolled on Phase I oncology trials.

Hyman DM, Eaton AA, Gounder MM, Pamer EG, Pettiford J, Carvajal RD, Ivy SP, Iasonos A, Spriggs DR.

Oncotarget. 2015 Aug 7;6(22):19316-27.

31.

Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors.

Hyman DM, Snyder AE, Carvajal RD, Gerecitano JF, Voss MH, Ho AL, Konner J, Winkelmann JL, Stasi MA, Monson KR, Iasonos A, Spriggs DR, Bialer P, Lacouture ME, Teitcher JB, Katabi N, Fury MG.

Cancer Chemother Pharmacol. 2015 Apr;75(4):747-55. doi: 10.1007/s00280-015-2693-z. Epub 2015 Feb 12.

32.

The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer.

Meisel JL, Hyman DM, Garg K, Zhou Q, Dao F, Bisogna M, Gao J, Schultz ND, Grisham RN, Phillips M, Iasonos A, Kauff ND, Levine DA, Soslow RA, Spriggs DR.

Ann Oncol. 2014 Dec;25(12):2372-8. doi: 10.1093/annonc/mdu461. Epub 2014 Oct 3.

33.

Reply to M. Voskoboynik et al.

Hyman DM, Eaton AA, Gounder MM, Ivy SP, Iasonos A, Spriggs DR.

J Clin Oncol. 2014 Oct 1;32(28):3199-200. doi: 10.1200/JCO.2014.56.5762. Epub 2014 Jul 28. No abstract available.

PMID:
25071117
34.

Medical service redesign shares the load saving 6000 bed days and improving morale.

Toomath R, Szecket N, Nahill A, Denison T, Spriggs D, Lay C, Wilkinson L, Poole P, Jordan A, Lees J, Millner S, Snow B.

Intern Med J. 2014 Aug;44(8):785-90. doi: 10.1111/imj.12477.

PMID:
24863137
35.

Diagnostic testing of blood donor specimens.

Spriggs D.

N Z Med J. 2014 Apr 11;127(1392):108-9. No abstract available.

PMID:
24806256
36.

Effect of Montanide and poly-ICLC adjuvant on human self/tumor antigen-specific CD4+ T cells in phase I overlapping long peptide vaccine trial.

Tsuji T, Sabbatini P, Jungbluth AA, Ritter E, Pan L, Ritter G, Ferran L, Spriggs D, Salazar AM, Gnjatic S.

Cancer Immunol Res. 2013 Nov;1(5):340-50. doi: 10.1158/2326-6066.CIR-13-0089. Epub 2013 Sep 16.

37.

Adverse cardiovascular, cerebrovascular, and peripheral vascular effects of marijuana: what cardiologists need to know.

Barber PA, Roberts S, Spriggs DA, Anderson NE.

Am J Cardiol. 2014 Mar 15;113(6):1086. doi: 10.1016/j.amjcard.2014.01.400. Epub 2014 Jan 30. No abstract available.

PMID:
24581721
38.

Nomogram to predict cycle-one serious drug-related toxicity in phase I oncology trials.

Hyman DM, Eaton AA, Gounder MM, Smith GL, Pamer EG, Hensley ML, Spriggs DR, Ivy P, Iasonos A.

J Clin Oncol. 2014 Feb 20;32(6):519-26. doi: 10.1200/JCO.2013.49.8808. Epub 2014 Jan 13.

39.

Intravenous aflibercept in patients with platinum-resistant, advanced ovarian cancer: results of a randomized, double-blind, phase 2, parallel-arm study.

Tew WP, Colombo N, Ray-Coquard I, Del Campo JM, Oza A, Pereira D, Mammoliti S, Matei D, Scambia G, Tonkin K, Shun Z, Sternas L, Spriggs DR.

Cancer. 2014 Feb 1;120(3):335-43. doi: 10.1002/cncr.28406. Epub 2013 Oct 11.

40.

Reply to M.L. Friedlander et al.

Spriggs DR.

J Clin Oncol. 2013 Jun 20;31(18):2363. No abstract available.

PMID:
23930276
41.

Lead poisoning from Ayurvedic medicines.

Tsutsui RS, Van Schalkwyk J, Spriggs D.

N Z Med J. 2013 May 10;126(1374):80-3.

PMID:
23799386
42.

Cannabis, ischemic stroke, and transient ischemic attack: a case-control study.

Barber PA, Pridmore HM, Krishnamurthy V, Roberts S, Spriggs DA, Carter KN, Anderson NE.

Stroke. 2013 Aug;44(8):2327-9. doi: 10.1161/STROKEAHA.113.001562. Epub 2013 May 21.

PMID:
23696547
43.

Effect of platelet inhibition with cangrelor during PCI on ischemic events.

Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW, Price MJ, Leonardi S, Gallup D, Bramucci E, Radke PW, Widimský P, Tousek F, Tauth J, Spriggs D, McLaurin BT, Angiolillo DJ, Généreux P, Liu T, Prats J, Todd M, Skerjanec S, White HD, Harrington RA; CHAMPION PHOENIX Investigators.

N Engl J Med. 2013 Apr 4;368(14):1303-13. doi: 10.1056/NEJMoa1300815. Epub 2013 Mar 10.

44.
45.

Vasculitis of the female genital tract: not always a localized condition.

West SC, Zwi LJ, Spriggs D, McQueen FM.

J Rheumatol. 2012 Nov;39(11):2229-30. doi: 10.3899/jrheum.120795. No abstract available.

PMID:
23118298
46.

Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients.

Sabbatini P, Tsuji T, Ferran L, Ritter E, Sedrak C, Tuballes K, Jungbluth AA, Ritter G, Aghajanian C, Bell-McGuinn K, Hensley ML, Konner J, Tew W, Spriggs DR, Hoffman EW, Venhaus R, Pan L, Salazar AM, Diefenbach CM, Old LJ, Gnjatic S.

Clin Cancer Res. 2012 Dec 1;18(23):6497-508. doi: 10.1158/1078-0432.CCR-12-2189. Epub 2012 Oct 2.

47.

Drug development for chronic cancers: time to think differently?

Spriggs DR.

J Clin Oncol. 2012 Nov 1;30(31):3779-80. doi: 10.1200/JCO.2012.42.3269. Epub 2012 Sep 17. No abstract available.

PMID:
22987092
48.

BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer.

Grisham RN, Iyer G, Garg K, Delair D, Hyman DM, Zhou Q, Iasonos A, Berger MF, Dao F, Spriggs DR, Levine DA, Aghajanian C, Solit DB.

Cancer. 2013 Feb 1;119(3):548-554. doi: 10.1002/cncr.27782. Epub 2012 Aug 28.

49.

The impact of non-drug-related toxicities on the estimation of the maximum tolerated dose in phase I trials.

Iasonos A, Gounder M, Spriggs DR, Gerecitano JF, Hyman DM, Zohar S, O'Quigley J.

Clin Cancer Res. 2012 Oct 1;18(19):5179-87. doi: 10.1158/1078-0432.CCR-12-0726. Epub 2012 Jul 23. Erratum in: Clin Cancer Res. 2013 Jan 1;19(1):306.

50.

Simple prescribing errors and allergy documentation in medical hospital admissions in Australia and New Zealand.

Barton L, Futtermenger J, Gaddi Y, Kang A, Rivers J, Spriggs D, Jenkins PF, Thompson CH, Thomas JS.

Clin Med (Lond). 2012 Apr;12(2):119-23.

Supplemental Content

Loading ...
Support Center